Universal Beteiligungs und Servicegesellschaft mbH Boosts Stake in Soleno Therapeutics, Inc. $SLNO

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 20.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,068 shares of the company’s stock after acquiring an additional 7,573 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Soleno Therapeutics worth $3,692,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Optimize Financial Inc bought a new stake in shares of Soleno Therapeutics during the 1st quarter valued at $274,000. Scientech Research LLC increased its stake in Soleno Therapeutics by 120.5% during the 1st quarter. Scientech Research LLC now owns 11,620 shares of the company’s stock valued at $830,000 after purchasing an additional 6,351 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of Soleno Therapeutics by 9.1% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 405,651 shares of the company’s stock valued at $33,985,000 after acquiring an additional 33,954 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Soleno Therapeutics by 16.0% in the 1st quarter. Woodline Partners LP now owns 349,664 shares of the company’s stock worth $24,983,000 after purchasing an additional 48,102 shares in the last quarter. Finally, Fred Alger Management LLC raised its position in Soleno Therapeutics by 172.8% in the 1st quarter. Fred Alger Management LLC now owns 40,394 shares of the company’s stock worth $2,886,000 after buying an additional 25,589 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on SLNO shares. Lifesci Capital raised shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 10th. Wolfe Research assumed coverage on Soleno Therapeutics in a report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price target on the stock. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $106.00 price objective (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. The Goldman Sachs Group set a $125.00 price objective on Soleno Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $110.00 target price (up previously from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Soleno Therapeutics currently has an average rating of “Buy” and a consensus price target of $111.46.

Soleno Therapeutics Trading Up 0.4%

Shares of SLNO stock opened at $45.11 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 15.13 and a quick ratio of 15.01. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -10.90 and a beta of -2.92. Soleno Therapeutics, Inc. has a 1 year low of $41.50 and a 1 year high of $90.32. The firm has a fifty day moving average price of $58.67 and a 200-day moving average price of $71.03.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million. As a group, equities analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.